Márk Plander

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation

Gero Brockhoff, Barbara Heckel, E. Schmidt‐Bruecken et al. · Cell Proliferation · 2007 · 87 citations · Full text

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles

Márk Plander, Silvia Seegers, Péter Ugocsai et al. · Leukemia · 2009 · 64 citations · Full text

Different Proliferative, Cell Division, Vitro Model +10

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Gergely Varga, Zsolt Nagy, Judit Demeter et al. · Pathology & Oncology Research · 2019 · 28 citations · Full text

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Szilvia Lovas, Gergely Varga, Péter Farkas et al. · International Journal of Hematology · 2019 · 27 citations

Daratumumab Treatment, Hematological Malignancy, Medicine +7